Menovo(SH:603538) Zheng Quan Zhi Xing·2025-04-02 14:34Summary of Key Points Core Viewpoint - The announcement details the conversion results of the convertible bonds issued by Ningbo Meinuo Pharmaceutical Co., Ltd., highlighting the amount converted and the remaining unconverted bonds as of March 31, 2025. Group 1: Conversion Status - As of March 31, 2025, a total of RMB 43,462,000 of "Meinuo Convertible Bonds" has been converted into company shares, resulting in 1,173,293 shares, which accounts for 0.784% of the total shares issued before the conversion [1][4]. - The amount of convertible bonds that have not been converted as of the same date is RMB 476,538,000, representing 91.642% of the total issuance [1][4]. - During the first quarter of 2025, the conversion amount was RMB 35,000, leading to the issuance of 1,350 shares [1][4]. Group 2: Convertible Bond Issuance Overview - The company was approved by the China Securities Regulatory Commission to publicly issue RMB 520 million of convertible bonds on January 14, 2021, with a maturity of 6 years and a tiered interest rate structure [2]. - The bonds were listed on the Shanghai Stock Exchange on February 4, 2021, under the name "Meinuo Convertible Bonds" with the code "113618" [2]. - The initial conversion price was set at RMB 37.47 per share, which has been adjusted multiple times due to various corporate actions, including cash dividends and stock incentive plans [2][3]. Group 3: Share Capital Changes - The total share capital before the conversion was 218,754,997 shares, which decreased to 218,609,075 shares after accounting for the conversion of 1,350 shares [5].